Thursday, March 14, 2013
Signifor® (Pasireotide) is now Commercially Available
November 7, 2012 The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously in support of the use of Signifor® (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention. The recommendation was based on data from clinical trials of pasireotide, including PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease), the largest randomized Phase III study to evaluate a medical therapy in patients with Cushing's disease.
Patient Assistance for SIGNIFOR support for patients includes:
- Therapy-specific support programs for out-of-pocket costs
- Alternative assistance searches and referrals to Federal and State assistance programs
- Referrals to Independent Charitable Foundations for assistance with co-pay costs
- Patient assistance for low-income and uninsured patients
For more information, or to speak to a Patient Assistance NOW Endocrinology representative, please call 1-877-503-3377 (select option #3 for SIGNIFOR) Monday to Friday 8 am - 8 pm ET.